Pharmaceuticals
News Releases
News releases related to other therapeutic areas
2024
Pharmaceuticals
Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
Pharmaceuticals
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Pharmaceuticals
Otsuka Enters into Investment Contract with AN Venture Partners
2023
2022
Pharmaceuticals
Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
Pharmaceuticals
Otsuka Measurement Kit to be Covered by National Health Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
Pharmaceuticals
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Pharmaceuticals
Launch in Japan of Moizerto® Ointment, a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
2021
Pharmaceuticals
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
Pharmaceuticals
Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
Pharmaceuticals
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
Pharmaceuticals
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuticals
New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB® for Treatment of Acid-Related Disease
Pharmaceuticals
Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
2020
Pharmaceuticals
Quick NaviTM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
Pharmaceuticals
Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
Pharmaceuticals
Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by Otsuka
Pharmaceuticals
Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension
Pharmaceuticals
Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuticals
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"
Pharmaceuticals
Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
Pharmaceuticals
Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -
Pharmaceuticals
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)
Pharmaceuticals
Cabpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
Pharmaceuticals
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
Pharmaceuticals
Otsuka Pharmaceutical Establishes Subsidiary in Malaysia
Pharmaceuticals
Otsuka enters multi-project drug discovery collaboration with PhoreMost Limited
2019
Pharmaceuticals
Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA® Combination Ophthalmic Solution
Pharmaceuticals
POConePlus® Infrared Spectrophotometer for Diagnosis of H. pylori infection launched in Japan
Pharmaceuticals
RS Virus Rapid-measurement Kit Quick NaviTM-RSV2 To Be Launched in Japan- Faster test results and enhanced visual features with two color lines -
Pharmaceuticals
The 1st Japan Open Innovation Prize
2018
Pharmaceuticals
Quick Navi-Reader for Diagnosis of Influenza to be Launched in Japan
Pharmaceuticals
Otsuka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis
Pharmaceuticals
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
2017
Pharmaceuticals
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Pharmaceuticals
Otsuka to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuticals
Otsuka and X-Chem Enter into a Drug Discovery Research and License Collaboration (PDF: 119.0 KB)
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
Pharmaceuticals
Otsuka Pharmaceutical to Launch New, Pre-mixed Flavor Formulations (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for Patients with Liver Failure
Pharmaceuticals
Otsuka Pharmaceutical Launches New Formulations in Japan of L-Cartin® for Carnitine Deficiencies
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)
Pharmaceuticals
"Quick Navi-Flu2" Influenza Diagnostic Kit to Launch in Japan
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)
Pharmaceuticals
Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan
Pharmaceuticals
Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
Pharmaceuticals
Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities
Pharmaceuticals
Osaka University and Otsuka Agree Comprehensive Collaboration : Joint Research Project with Immunology Frontier Research Center (IFReC) (PDF: 226.3 KB)
Pharmaceuticals
Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan
2016
Pharmaceuticals
Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
Pharmaceuticals
Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)
Pharmaceuticals
RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launches (PDF: 90.0 KB)
Pharmaceuticals
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdominal CT Scans, Launched in U.S. Developed by Otsuka Subsidiary Interpharma Praha
Pharmaceuticals
Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.
Pharmaceuticals
VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION®pack (triple-drug blister packs containing TAKECAB® tablet) Now Available for Helicobacter pylori* Eradication in Japan
Pharmaceuticals
Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
Pharmaceuticals
Takeda Obtains NDA Approval for Helicobacter pylori* Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP® pack 400", "VONOSAP® pack 800" and "VONOPION® pack" in Japan
Pharmaceuticals
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
Pharmaceuticals
Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis
2015
Pharmaceuticals
Winner Announced for the 2015 Young Innovator in TB Research Award
Pharmaceuticals
New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
Pharmaceuticals
Efficacy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
Otsuka's JINARC® the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
Pharmaceuticals
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuticals
New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
Pharmaceuticals
The Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
Pharmaceuticals
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
Pharmaceuticals
CHMP Recommends JINARC® (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease
Pharmaceuticals
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
Pharmaceuticals
Terminations of Otsuka's Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine for Pancreatic Cancer and Otsuka's Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102
2014
Pharmaceuticals
New Drug Application Approval of TAKECAB® for the Treatment of Acid-related Diseases in Japan
Pharmaceuticals
ARIAD and Otsuka Announced Co-development and Commercialization Agreement for Iclusig® to Treat Leukemias in Japan and Nine Other Asian Countries
Pharmaceuticals
Otsuka And Lundbeck's Brexpiprazole Demonstrates Statistically Significant Effects In New Phase III Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting
Pharmaceuticals
Otsuka And Lundbeck Present Phase III Data on Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting
Pharmaceuticals
U.S. FDA Approves The Labeling Update Of Abilify Maintena ® (Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clinical Data For The Treatment Of Acutely Relapsed Adults With Schizophrenia
Pharmaceuticals
L-Cartin® FF Tablets For Carnitine Deficiencies To Be Introduced in Japan on December 5 Active Ingredient Carnitine in Free Form (FF*) to Address the Needs of Medical Field
Pharmaceuticals
Otsuka Pharmaceutical's QuickNavi™-Flu Influenza Diagnostic Kit to Provide Additional Diagnosis-Related Information
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka's Major BCR-ABL mRNA Measurement Kit
Pharmaceuticals
A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26
Pharmaceuticals
After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
Pharmaceuticals
Regulatory Approval Received in Japan For L-Cartin® FF Tablets 100 mg・250 mg Doses That Incorporate Carnitine in Free Form (FF*) Enables Medical Professionals to Conveniently Switch Patients Among the Three Free-Form Formulations – Tablet, Oral Solution and Injection
Pharmaceuticals
Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100Puffs
Pharmaceuticals
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)
2013
Pharmaceuticals
CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Pharmaceuticals
Otsuka Named as Lundbeck's Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption
Pharmaceuticals
Otsuka Pharmaceutical Receives the 2013 Good Design Award for the Antiplatelet Drug "Pletaal® OD Tablets"
Pharmaceuticals
Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease
Pharmaceuticals
Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launched on August 29
Pharmaceuticals
U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Against Approval of Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Fingraph®, a fingertip blood sampler that conveniently measures sodium and potassium electrolyes in just one minute, debuts in Japan on August 6
Pharmaceuticals
Otsuka Receives Opinion from CHMP on Delamanid
Pharmaceuticals
Otsuka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK
Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting
Pharmaceuticals
Otsuka Pharmaceutical's 44-member Employee Dance Group "Otsuka-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark
Pharmaceuticals
Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
Pharmaceuticals
Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin
Pharmaceuticals
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms for Carnitine Deficiency To Be Launched on February 26
Pharmaceuticals
7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist
Pharmaceuticals
Otsuka Pharmaceutical Files for Application of New Dry Powder Inhaler Product from the Meptin Brand
2012
Pharmaceuticals
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms approved for Carnitine Deficiency
Pharmaceuticals
The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
Pharmaceuticals
Otsuka Pharmaceutical and Abdi İbrahim Established a Joint Venture Company for Pharmaceutical Sales in Turkey
Pharmaceuticals
Vasopressin V2-Receptor Antagonist, Samsca® Tablets Were Filed Additional Indication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
Pharmaceuticals
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
Pharmaceuticals
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
Pharmaceuticals
The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
Pharmaceuticals
Mucosta® ophthalmic suspension UD2% releases on January 5, 2012
2011
Pharmaceuticals
Streptococcus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic releases on December 1
Pharmaceuticals
Results of two trials show a rapid and sustained response with certolizumab pegol for treatment of rheumatoid arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of American College of Rheumatology (ACR)
Pharmaceuticals
Otsuka Pharmaceutical Confirmed Clinical Efficacy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clinical Study in Japan
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.
Pharmaceuticals
The IFPMA Welcomes Otsuka Pharmaceutical as New Member to advance Global Health
Pharmaceuticals
Otsuka receives approval for Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as in vitro diagnostic on June 13
Corporate
Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilitate Public Advocacy for the Company's Global Tuberculosis Program
Pharmaceuticals
Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011
Pharmaceuticals
Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin® tablets for Carnitine Deficiency in Japan
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes
Pharmaceuticals
Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuticals
World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Samsca® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14
Pharmaceuticals
Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
Corporate
Otsuka Prevails in U.S. Abilify® Patent Litigation
Pharmaceuticals
Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye
Pharmaceuticals
SAMSCA™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
Pharmaceuticals
Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010
Pharmaceuticals
Otsuka Pharmaceutical to Introduce 1,300 iPad™ Units for Use as Multifunctional Pharmaceutical Information Tools
Pharmaceuticals
Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26
Corporate
Core of Global Basic Research Drug Discovery Research Building "10th Research Center" Completed on April 26
Pharmaceuticals
Groundbreaking Ceremony for New Plant to Manufacture Active Pharmaceutical Ingredients held on April 8 at Saga Factory
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50
Pharmaceuticals
FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography
Pharmaceuticals
Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Corporate
Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102
2009
Pharmaceuticals
The European Commission Approves SAMSCA™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .
Pharmaceuticals
FDA Approves SAMSCA™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia
2008
Corporate
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
Corporate
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration
Corporate
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye
Corporate
Otsuka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic
2007
2006
Corporate
Strategic partnership agreement between Otsuka Pharmaceutical Co., Ltd. ('Otsuka Pharmaceutical') and Eiken Chemical Co., Ltd. ('Eiken Chemical') accompanied by the acquisition of a strategic stake in Eiken Chemical by Otsuka Pharmaceutical
Pharmaceuticals